CLRB vs. ADVM, ANL, IFRX, HOWL, DRRX, DTIL, IZTC, IMA, CLNN, and ATNM
Should you be buying Cellectar Biosciences stock or one of its competitors? The main competitors of Cellectar Biosciences include Adverum Biotechnologies (ADVM), Adlai Nortye (ANL), InflaRx (IFRX), Werewolf Therapeutics (HOWL), DURECT (DRRX), Precision BioSciences (DTIL), Invizyne Technologies (IZTC), ImageneBio (IMA), Clene (CLNN), and Actinium Pharmaceuticals (ATNM). These companies are all part of the "pharmaceutical products" industry.
Cellectar Biosciences vs. Its Competitors
Adverum Biotechnologies (NASDAQ:ADVM) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.
Adverum Biotechnologies has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Cellectar Biosciences has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500.
In the previous week, Cellectar Biosciences had 2 more articles in the media than Adverum Biotechnologies. MarketBeat recorded 3 mentions for Cellectar Biosciences and 1 mentions for Adverum Biotechnologies. Cellectar Biosciences' average media sentiment score of 0.61 beat Adverum Biotechnologies' score of 0.44 indicating that Cellectar Biosciences is being referred to more favorably in the news media.
48.2% of Adverum Biotechnologies shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 6.0% of Adverum Biotechnologies shares are owned by insiders. Comparatively, 5.0% of Cellectar Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Adverum Biotechnologies' return on equity of -297.29% beat Cellectar Biosciences' return on equity.
Adverum Biotechnologies currently has a consensus price target of $19.75, indicating a potential upside of 545.85%. Cellectar Biosciences has a consensus price target of $375.00, indicating a potential upside of 7,512.67%. Given Cellectar Biosciences' higher possible upside, analysts clearly believe Cellectar Biosciences is more favorable than Adverum Biotechnologies.
Cellectar Biosciences has lower revenue, but higher earnings than Adverum Biotechnologies. Adverum Biotechnologies is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Adverum Biotechnologies beats Cellectar Biosciences on 9 of the 14 factors compared between the two stocks.
Get Cellectar Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CLRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cellectar Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:CLRB) was last updated on 8/28/2025 by MarketBeat.com Staff
MarketBeat All Access